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Abstract
High-throughput sequencing platforms provide an approach for detecting rare HIV-1 variants and documenting more fully
quasispecies diversity. We applied this technology to the V3 loop-coding region of env in samples collected from 4
chronically HIV-infected subjects in whom CCR5 antagonist (vicriviroc [VVC]) therapy failed. Between 25,000–140,000
amplified sequences were obtained per sample. Profound baseline V3 loop sequence heterogeneity existed; predicted
CXCR4-using populations were identified in a largely CCR5-using population. The V3 loop forms associated with subsequent
virologic failure, either through CXCR4 use or the emergence of high-level VVC resistance, were present as minor variants at
0.8–2.8% of baseline samples. Extreme, rapid shifts in population frequencies toward these forms occurred, and deep
sequencing provided a detailed view of the rapid evolutionary impact of VVC selection. Greater V3 diversity was observed
post-selection. This previously unreported degree of V3 loop sequence diversity has implications for viral pathogenesis,
vaccine design, and the optimal use of HIV-1 CCR5 antagonists.
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Introduction
Infection with human immunodeficiency virus (HIV) is charac-
terized by extensive viral diversity due to the high error rate of the
reverse transcriptase, rapid viral turnover, and the impact of
immune selection. Clonal analysis, single genome sequencing, and
modeling provide evidence for the complex quasispecies nature of
HIV-1 within infected individuals, but practical considerations have
limited researchers’ ability to document the true extent of viral
heterogeneity. The advent of novel sequencing platforms that allow
‘‘deep’’ pyrosequencing of the HIV quasispecies provides an
opportunity to confirm the previously hypothesized diversity of
HIV-1 and to track the dynamic evolution of the quasispecies in
response to a selection pressure.
Sequencing-by-synthesis technologies generate data by repeti-
tive sequencing, or oversampling, of a given DNA segment and
can be adapted to sequence one particular DNA region at great
depth [1–3]. We used this approach to quantify and track diversity
under drug selection pressure by sequencing V3 loop amplicons
derived from plasma HIV-1 RNA of subjects receiving vicriviroc
(VVC), an investigational CCR5 antagonist that inhibits HIV-1
entry [4]. The V3 loop of HIV-1 gp120 is the main determinant of
viral cellular tropism, allowing the virus to use either the host cell
surface proteins CCR5 (R5 viruses), CXCR4 (X4 viruses), or both
(dual-tropic [D/M] viruses) as a coreceptor for entry [5–8]. CCR5
is used almost exclusively for entry in early infection, but CXCR4-
using viruses associated with greater morbidity and mortality
emerge in approximately 50% of patients over the course of
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gp120-CCR5 interaction has re-emphasized the need to improve
our understanding of coreceptor usage [13]. In patients failing
therapy with the CCR5 antagonist maraviroc, the dominant route
of HIV escape was the emergence of CXCR4-using viral
populations and not the development of conventional resistance
[14,15]. Algorithms to predict CXCR4 usage based on population
sequencing of the V3 loop-coding region of env have low sensitivity
for detecting X4 or D/M viruses in clinical samples [16]. For this
reason, clinical trials of CCR5 antagonists have used a validated
phenotypic assay to determine HIV-1 coreceptor usage and
exclude patients with detectable CXCR4-using virus [17]. A
phylogenetic analysis of viral sequences sampled from the time of
maraviroc failure in two subjects suggested that CXCR4-using
virus emerged on therapy from minor CXCR4-using viral
populations that were not detected by the phenotypic assay [18].
New technologies that allow massively parallel sequencing of
individual viruses in the HIV quasispecies could provide an
improved representation of V3 diversity within a patient, and shed
new light on the extent to which minor CXCR4-using populations
and/or CCR5-using variants with reduced susceptibility to CCR5
antagonists circulate prior to CCR5 antagonist therapy [19].
Results
Validation of quantitative deep sequencing
Before we amplified and subjected patient samples to deep
sequencing, we conducted duplicate control experiments to assess
the effects of PCR amplification and deep sequencing with 454
technology on amplicon quantification and error rates using 3
clones from subject 07 at an input ratio of 89:10:1. The ratio was
well preserved through the initial amplification and after post-
processing filtering to exclude problematic sequences and to trim
error-prone ends. These results indicated that no strong
quantitative biases were introduced by the experimental or
computational processing methods within the sensitivity of the
control experiment (Table S1, Figs. S1, S2), confirming that
quantification was reproducible for variants found at frequencies
at least as low as 1%. After applying the filtering steps in the two
controls, approximately 4.5% of sequences had one or more
nucleotide differences from one of the three input sequences. Most
of these (.99.8%) differed by only a single amino acid from one of
the input sequences; the remainder (,0.2%) differed by more than
one amino acid mismatch (Tables S1 and S2). Recombination
was infrequently observed, but could only be clearly resolved when
comparing the sequence present in the input 1% with the other
two. The per-nucleotide error rate was 0.0011 and 0.0016 for the
two control experiments, respectively, reflecting the error
introduced by our combined amplification and deep sequencing
protocol that remained after filtering out problematic sequences.
For similar clones that differ by one nucleotide, our control
experiments demonstrated a threshold of detection between 0.10–
0.21%. We could not distinguish a true sequence difference from
differences introduced by amplification errors or biases below this
threshold. The threshold of detection necessarily decreased as the
number of nucleotide differences increased.
To assess the reproducibility of sequence proportions deter-
mined by deep sequencing, we performed 4 replicate amplification
reactions using identical input HIV-1 RNA (Supplementary
Methods S1, section 2.2). The mean percentage (6SD) of a
minor CXCR4-using variant obtained was 2.4260.55%. The
coefficient of variation was 22.8%, suggesting that for smaller
fractions the absolute proportion measured by 454 sequencing can
vary substantially around the true value.
Subject selection, deep sequencing, data filtering and
alignment
We selected subjects enrolled in a phase IIb clinical trial of VVC
who experienced protocol-defined virologic failure (,1 log10 viral
load decrease at or after week 16) and a change in coreceptor
usage as determined by a validated phenotypic assay (Trofile,
Monogram Biosciences, South San Francisco, CA); subjects with
assay-detectable CXCR4-using virus at baseline were excluded
[13]. Per study protocol, all subjects received VVC for 2 weeks
(baseline to week 2) prior to optimization of their background
antiretroviral regimen. Three subjects met these criteria: subjects
18 and 19 had a rapid change to CXCR4-using virus whereas
subject 07 developed high-level VVC resistance and had late
emergence of a minority X4 population (Fig. 1). Subject 07 was
infected with a subtype C virus, the others with subtype B; subtype
C infections infrequently exhibit a CXCR4-using phenotype [20].
A fourth subject, subject 47, who had virologic failure without a
change in coreceptor usage or VVC susceptibility served as a
comparison. All subjects were receiving VVC at the time of
virologic failure, but subject 19 had poor adherence and low VVC
concentrations prior to virologic failure (data not shown). Three
time points were analyzed for each subject: study entry (week 0),
an intermediate time point while receiving VVC, and virologic
failure. The first time point at which CXCR4-using virus was
detected by the Trofile assay was selected as the intermediate time
point for each subject; this occurred at week 2 for subjects 18 and
19. If CXCR4-using virus was not detected before virologic failure
(subjects 07 and 47), we used the next time point after week 0 for
which subject plasma was available as the intermediate time point.
At baseline and week 2, genotypic susceptibility scores (GSS) were
0.0 and 0.37 for subject 07, 0.0 and 1.3 for subject 18, and 0.02
and 0.45 for subject 47, respectively (subject 19 did not have
genotypic resistance data for either time point). Phenotypic
susceptibility scores (PSS) at baseline and week 2 were 0.14 and
1.17 for subject 07, 0.0 and 1.88 for subject 18, 0.92 and 1.75 for
subject 19, and 0.19 and 0.93 for subject 47, respectively.
Plasma HIV-1 RNA and subject-specific primer sets were used
to reverse transcribe and amplify V3 loop-coding segments;
amplicons were then sequenced in a blinded fashion using 454
technology [3]. Between 25,000–140,000 sequences were obtained
per sample (Table S3). Real-time RT-PCR with SYBR green
detection was performed for a subset of plasma samples to quantify
the number of viral RNA templates being amplified with our
primer sets (Supplementary Methods S1, Section 1.3). These
data indicate that the proportion of templates amplified varied
between 26–61% of the total templates available. Given the
sequence heterogeneity within env, our use of subject-specific
primer sets with degeneracy may represent a ‘‘best-case’’ scenario
for template amplification; the use of primers based on consensus
sequences could result in less efficient amplification.
Raw nucleotide sequences were filtered, aligned, trimmed and
translated using pre-specified criteria applied uniformly so that all
V3 sequence forms included in subsequent analyses spanned the
complete V3 loop and the two proximal N-linked glycosylation
sites. These filtering steps retained 80–95% of the original
sequences for subsequent analyses, with the exception of one
sample from subject 18 that had a higher proportion of sequences
excluded due to a recurring frameshifting mutation (Table S3).
Quasispecies V3 composition at baseline
Baseline samples demonstrated considerable V3 loop sequence
heterogeneity. In all subjects, about half (44–59%) of the baseline viral
population consisted of a single dominant R5 V3 form; the three most
common baseline forms accounted for the majority (86–93%) of the
V3 Loop Deep Sequencing
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population consisted ofhundreds or thousands oflow frequency minor
forms, even over the very short region of the V3 loop (117 bases, or 39
amino acids) that was the focus of the study. Subjects 18 and 19 had a
number of forms that were predicted and/or phenotypically
confirmed to be X4, (Figs. 2b,c, Tables S4, S5) showing that rare
X4 sequences can co-exist within a dominant R5 population at levels
undetectable by conventional methods. Because subject 07 was
infected with an HIV-1 subtype C virus, accurate prediction of
CXCR4 usage by genotype was precluded. However, phenotypic
testing (Trofile) of the uncloned plasma virus population indicated
exclusive CCR5 use at the time points studied with 454 sequencing
(Figure 2a). Subject 47, who did not exhibit a coreceptorchange, had
very few predicted baseline X4 V3 forms and, as will be described,
relatively restricted V3 diversity (Figure 2d and Table S6).
Rapid selection of pre-existing minor V3 loop variants
under VVC pressure
By week 2 of VVC treatment, frequencies of the dominant R5
V3 forms in subjects 18 and 19 fell, while those of select minor
CXCR4-using forms rose dramatically (Figs. 2b,c). In subject 18,
the three most common baseline forms declined from a total of
86% to just 1.5% of the V3 loop population, while a CXCR4-
using form present at 0.8% of baseline sequences rose to 85%. In
subject 19, the three most common baseline forms fell from a
combined prevalence of 90% to 38%, while an X4 form that was
again present at 0.8% at baseline rose to become the most
common form (44%) at week 2. By week 12, subject 07 showed a
similar pattern. The three most common baseline forms, which
constituted 85% of the population declined to 22%, while three
forms that were present at a combined prevalence of 3% at
baseline rose to 52% of the population. No CXCR4-using virus
was detected, however, and the forms that increased in prevalence
during VVC treatment are known from earlier work to confer
VVC resistance [21]. Subject 47, in whom two R5 forms that
differed at a single amino acid position were present at baseline
(N308 vs. H308, 59 and 34% respectively), had a switch in
dominant forms without the emergence of CXCR4-using virus or
VVC resistance (Fig. 2d). The H308-containing form rose to 92%
at weeks 18 and 19, suggesting a relative fitness advantage of this
Figure 1. Plasma HIV-1 RNA levels, coreceptor usage and sequence coverage for four subjects failing VVC therapy. (A) Subject 07, (B)
Subject 18, (C) Subject 19, (D) Subject 47. Protocol-defined virologic failure was defined as ,1 log10 viral load decrease from baseline at or after week
16. Coreceptor usage was determined phenotypically by the Trofile assay; R5, CCR5-using virus only detected; DM, both CCR5- and CXCR4-using
viruses detected. Vertical black arrows indicate time points sampled for V3 loop sequencing. The bars indicate the extent of coverage by deep
sequencing.
doi:10.1371/journal.pone.0005683.g001
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dominant at the later time points were present as minor variants in
the baseline populations.
A subset of CXCR4-using forms that rose to plurality in subject
18 during VVC treatment persisted through week 16. In subject
19, self-reported non-adherence and low plasma VVC levels at
week 8 were accompanied by a resurgence of the three most
common CCR5-using baseline forms (Fig. 2c). The CXCR4-
using form that was most common while the subject remained
adherent fell 6-fold from 44% at week 2 to 7.5% at week 17.
Evolutionary impact of VVC selection
Figure 3 shows a neighbor joining (NJ) tree of all unique forms
found in subject 18, selected as a representative case; the NJ trees
of the other 3 cases are provided in the supplement (Figure S3).
This tree illustrates both the clear evolutionary trajectory of the
virus over 16 weeks of sampling, and the complexity of the V3
loop at baseline. There were 1,910 unique variants in this 39-
amino acid fragment of the virus in these samples. A remarkable
diversity of forms was already present in the baseline sample. The
majority of these forms are expected to represent true biological
variants, rather than PCR or sequencing artifact, given the
relatively small fraction of experimental error that remained in the
sequences after processing (see above discussion and compare
Fig 3 with the control tree shown in Fig S2). The most common
form of the V3 loop at week 0 was found in only 0.4% of the
sequences at week 2, and was lost by week 16. There was
significant selection for a single lineage at the second time point
(week 2), with one X4 sequence from that lineage making up 91%
of the sample; this form of the V3 loop continued to be the most
common form at the third time point (week 16), persisting at 70%.
Interestingly, despite a genetic bottleneck imposed by VVC, many
minor related variants within the selected lineage persisted at low
levels and continued to evolve alongside the dominant X4 form.
This point can be visualized in the tree by the acquisition and
building of new variants from the many variants present at week 0
within the selected lineage, and by the left to right progression
from week 0 to 2 to 16 (yellow to red to blue) within that lineage.
Two distinctive novel lineages were detected at week 16,
constituting 4% and 5% of the sample, respectively. The branch
Figure 2. Longitudinal changes in V3 loop forms and proportions. (A) Subject 07, (B) Subject 18, (C) Subject 19, and (D) Subject 47. The
most common V3 loop sequences across all three time points are numbered and displayed along the x-axis of the 3D-bar graph; corresponding
amino acid sequences are shown below the graphs. The relative contribution of each sequence is plotted on the y-axis and displayed as a proportion
of the total population. Time in weeks are shown on the z-axis. A coreceptor usage prediction using PSSM is shown for each sequence [32].
Coreceptor usage was measured phenotypically in sub07 by generating recombinant viruses that incorporated each V3 loop sequence. Vertical
arrows denote positions 11 and 25 in the V3 loop, respectively.
doi:10.1371/journal.pone.0005683.g002
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PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5683Figure 3. Neighbor-joining (NJ) tree over time for subject 18. All unique V3 forms found are included, and the frequency of the 3 most
common nucleotide forms indicated at each time point. The most common sequence at the first time point was used as an out-group for the trees.
Week 0, yellow; week 2, red; week 16 (virologic failure), blue. We have indicated the location and frequency of the most common sequence at each
time point, and the predominant lineage after selection.
doi:10.1371/journal.pone.0005683.g003
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relationships among baseline sequences. These findings suggest
that rather than rapidly replacing the susceptible form of the virus
with a single X4 variant, new levels of diversity in the V3 loop
were explored under the selective pressure of VVC. Many variants
were carried forward and continuing evolutionary pressure drove
de novo exploration of the sequence space.
Comparable sequence phylogenies for subjects 7 and 19 share
interesting features with subject 18 (Fig S3, S4, S5). All three show
extreme baseline diversity, selection of a favored lineage at the
second time point (rather than a single escape variant), and the
emergence under VVC selection of distinctive lineages with
relatively long branch lengths compared to the baseline sequences.
The emergence of novel forms that evolved from the population
suggests that the virus may have the opportunity to explore
previously unvisited sectors of sequence space after drug pressure
selects against the previously dominant baseline form(s). In subject
19, non-adherence to the VVC regimen was associated not with
reversion to the most common baseline sequence, but with
outgrowth of one of the other major lineages present at baseline
(Fig 2c and Fig S3, S4, S5). Virus from subject 47, in whom
virologic failure was not associated with emergence of VVC
resistance or CXCR4-using variants, had much lower diversity
overall over time.
The NJ trees enable an overview of each of the unique forms of
the virus and their relationships, but these trees do not capture the
rapidly shifting frequencies of the viral forms—the most striking
manifestation of the VVC selection—in the context of their
evolutionary trajectory. Thus, maximum likelihood (ML) trees
including only sequences found at frequencies greater than 0.1%
of the populations are also provided. These trees label unique
sequences by the magnitude of their population frequency. Again,
subject 18 is used as the example in Fig 4; ML trees for the control
experiments and for the remaining 3 subjects are provided in the
supplement (Fig S1 and S4, respectively). As each sequence
included in this analysis is repeated many times in a sample, all
variants included in the ML tree are likely to be found in vivo. For
the ML trees, the key amino acid sequences that typify emerging
clades are shown. The most common baseline sequence was used
as an outgroup for both the NJ and ML trees, allowing
visualization of population shifts and the acquisition of new viral
forms building off of the spectrum of baseline variants, with a clear
progression over time (Figs. 3, 4, S3, S4, S5).
Very unusual forms of the V3 loops, including some that do not
have an obvious conserved GPG turn at the tip, were found at the
third time point in subject 18 (Fig 4). These forms were primarily
the result of compensatory frameshifts within this short region. As
part of our processing strategy, we excluded all sequences with
frame-shift errors that are not compensated for, but we retained
frameshifts with paired nearby compensatory insertion-deletion
patterns, as HIV frequently uses compensatory frame-shifting as a
means of adaption [22]. Single base insertions or deletions are a
common experimental error in 454, however, particularly in
homopolymer reads due to the non-linearity of the signal [23].
Therefore, compensatory paired 454 errors could be a trivial
explanation of these odd V3 sequences. The particular array of
frame-shifting mutations that gave rise to the two clusters observed
in subject 18, however, are not all embedded in strings of like
bases. It is possible that the unusual V3 sequences may be viable
despite their very distinctive form, as they do not represent
common 454 errors in the earlier points from this subject, but are
common only in the third sample after 16 weeks under selective
pressure. In addition, these sequences represent clusters of variants
suggestive of evolutionary progression. Thus the source of the
unusual pattern–experiment error or biological variation– remains
unresolved. The long branch-lengths reflect alignments optimized
to provide intact reading frames and are not representative of base
changes, and so they reflect the divergence of the translated loop at
the amino acid level.
Deep sequencing also enabled tracking of temporal changes in
the proportions of the predicted minority X4 V3 forms that were
present at baseline in study subjects (Tables S4, S5, S6). Here,
patterns were mixed. Some forms increased in frequency, while
others decreased or disappeared.
Changes in Shannon Entropy over Time
Each unique V3 form at each time point was considered, and
the number of times each form appears was used to calculate the
Shannon entropy of the sample (Fig 5). In this analysis the V3
loop is being treated as a functional unit, and every distinct form
considered independently of distance measures, to obtain a
different perspective regarding population complexity. The 95%
confidence intervals (CI) for the Shannon Entropy were calculated
by 100 random-with-replacement re-samples (bootstrap) of the
primary V3 loop data at each time point. To illustrate the sample
diversity for each point, we plotted the number of times each form
was found on the y-axis, by the number of forms found with given
frequency on the x-axis. Thus, at week 0 for subject 07 there were
112,818 V3 sequences that were intact with no frame shifts or stop
codons (N=112,818). The most common sequence was found
56,546 times (the top left hand point). There were 585 unique
sequences that might be viable as they were intact in the V3
region, but they were each found only once in the sample (gold
point on the bottom right). The Shannon entropy, H, was 1.83
[95% CI 1.81–1.84]; the 95% CI of the entropy for this time point
and the next did not overlap, so the second sample was
significantly more diverse. After VVC selection, the total V3
diversity increased in each subject with emergent X4 or VVC-
resistant virus, corresponding to a significant increase in the overall
sample Shannon entropy in subjects 07 and 19. The seeming
paradox of increasing entropy of V3 forms upon selection in these
cases suggests that the resistant viruses may have the opportunity
to explore sequence space and variants can compete more
effectively after drug pressure selects against the previously
dominant and fit baseline form(s).
Discussion
Deep sequencing affords multiple advantages over current
sequencing techniques for the detection of minority HIV variants.
Co-linear sequence can be obtained in areas of significant genetic
heterogeneity, characteristic of HIV env, and at a faster speed and
greater depth than conventional cloning or single genome
sequencing. We developed a rigorous methodology for the filtering
and validation of quantitative deep sequencing in the context of
viral infections that can readily be applied to other deep sequence
data sets. Quantitative deep sequencing of plasma samples from
subjects failing a CCR5 antagonist-containing regimen provided
orders of magnitude greater coverage than previously possible and
revealed that minor V3 loop sequence variants have significant
clinical implications in chronic HIV-1 infection. We directly
demonstrated the previously hypothesized vast diversity of intra-
patient HIV sequences, in this case within a variable determinant
of viral coreceptor usage, and quantified the dynamic sequence
variation over time [24].
Although variants using either CXCR4 or CCR5 are known to
coexist in plasma, deep sequencing detected a multitude of distinct
co-circulating V3 forms and highlighted the extraordinary
V3 Loop Deep Sequencing
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5683Figure 4. Maximum Likelihood (ML) tree of the unique V3 forms for subject 18. These trees include only sequences found in more than
0.1% of the total. Amino acid sequences at branch points are shown. Week 0, yellow; week 2, red; week 16 (virologic failure), blue. The size of the box
at each leaf node indicates the frequency of the occurrence of the sequence.
doi:10.1371/journal.pone.0005683.g004
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changing fitness environments. Variants with predicted CXCR4
usage as well as VVC-resistant variants that emerged during VVC
treatment were shown to exist as uncommon or rare forms in
baseline samples in three of the four subjects we studied. These
rare forms differ from the dominant V3 form at multiple amino
acid positions and exist at greater frequencies than the single cycle
mutation rate of HIV (10
25–10
24 per base per cycle) or the
observed in vivo frequencies of non-nucleoside reverse transcrip-
tase or protease inhibitor resistance mutations (0.03% and 0.03%,
Figure 5. Shannon Entropy Plots. The number of times each form is found is plotted against the number of forms found with a given frequency.
Week 0, yellow; intermediate time point, red; VF, blue. 95% CI for the Shannon Entropy are calculated by 100 bootstrap re-samples of the distribution
of forms at each time point. The rise and decline of the two most common forms at each time point are tracked through the figures and are
represented by the colored lines; the coloring of these lines facilitates tracking the most common forms at the first time point (yellow), second time
point (red), and third time point (blue) through the time sequence.
doi:10.1371/journal.pone.0005683.g005
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This finding suggests that these V3 loops are not generated and
lost with each replication cycle, but in fact may be maintained as
minority variants during chronic infection. The documentation of
extensive V3 sequence diversity, coupled with the rapid expansion
of rare variants in response to a drug selection pressure highlights
the extraordinary challenge HIV diversity poses for preventive or
therapeutic vaccines targeting areas of similar sequence heteroge-
neity. These data further provide compelling evidence that
minority HIV variants present at less than 1% of the HIV-1
population in plasma are clinically relevant. The level of a
minority variant that is clinically relevant most likely varies as a
function of the potency of the background antiretroviral regimen,
underscoring the importance of combining several potent agents
when constructing antiretroviral regimens.
The reason subject 47 experienced treatment failure remains
unclear. The low GSS and PSS of this subject’s antiretroviral
regimen, determined at baseline and week 2, suggest that limited
potency of the antiretroviral regimen was the most likely explanation
for failure to achieve or maintain a 1-log10 reduction in viral load.
Subject adherence and plasma VVC levels were adequate, and no
changes were observed in coreceptor tropism, phenotypically or
genetically. Although most mutations that confer CCR5 antagonist
resistance map to the V3 loop, sequence changes in other regions of
env havebeennoted (MLewis,etal,15
thConferenceonRetroviruses
and Opportunistic Infections, February 5–8, 2008, Boston, MA,
Abstract 817) [21,28,29]. It is possible that sequence changes in env
outsideoftheV3loopcouldhavecontributedtovirologicfailure,but
phenotypic testing with full-length env constructs from subject 47 did
not demonstrate any loss of VVC susceptibility.
Our analysis has important limitations. Some error is inevitably
introduced through these experimental methods and it is not
obvious preciselywhichofthe rare formsarethe consequenceofthis
sequencing error. Furthermore, the longitudinal nature of the data
allowed tracking of frequency shifts in interesting sequences that
were subject to VVC selection pressure. Because of the limited
length of the sequences, homoplasy rather than shared lineages may
underlie some of the observed clustering patterns in the trees, and in
vitrorecombinationduringamplification may also havecontributed
to some of the apparent clades [30]. The trees are not expected to
provide accurate renditions of the phylogenies as they are by
necessity constrained by limitations imposed by the nature of the
data (very short sequences, convergence in a scenario of emerging
drug resistance, recombination, critical mutations occurring by
insertion and deletion), and are based on thousands of short
fragments with some experimental error. However, they do capture
the complexity of the samples, as well as the rapid temporal shifts in
the evolutionary landscape as a consequence of selective pressure.
Clear evolutionary progression over time was evident in each
subject. Multiple co-circulating minor CXCR4-using viruses were
found to exist in chronic infection, and the virus simultaneously
explored many escape routes as the drug-susceptible form was
selected against. The process of escape may push the virus towards
sampling unexplored regionsofthe sequencespace.Takentogether,
our data demonstrate the feasibility and utility of harnessing deep
sequencing platforms to comprehensively assess viral diversity,
quantify minor sequence variants, and provide insight into the
mechanisms of viral escape from novel CCR5 antagonists.
Methods
Subject Selection
We selected subjects enrolled in a phase IIb clinical trial of VVC
who experienced protocol-defined virologic failure and a change
in coreceptor usage as determined by a validated phenotypic assay
(Trofile, Monogram Biosciences, South San Francisco, CA),
excluding subjects with assay-detectable CXCR4-using virus at
baseline [13]. Plasma samples were required to have HIV-1 RNA
levels $5,000 copies/mL at all time points analyzed. Genotypic
and phenotypic susceptibility scores were calculated at baseline
(week 0) and week 2.
RNA Preparation
Virus from 500–1,400 mL of plasma was pelleted by centrifu-
gation (17,0006g, 1 hr, 4uC), resuspended in 140 mL of plasma,
and extracted using the QIAamp viral RNA mini kit according to
the manufacturer’s instructions (Qiagen, Valencia, CA; see
Supplementary Methods S1 for sample-specific plasma
volumes). The entire derived volume of extracted RNA (60 mL)
was used for cDNA synthesis. The range of the maximum RNA
copy number extracted from clinical samples was 18,000–793,000
(as quantified by the HIV-1 Monitor assay [Roche Molecular
Systems, Pleasanton, CA]), depending on available plasma volume
and total viral load in a given sample. The actual number of viral
templates amplified with our protocol was determined for three
samples (see Template Number Validation below).
Primer Design
Given the heterogeneity of envelope sequences in the region
flanking the V3 loop, subject-specific primers were designed for
cDNA synthesis and DNA amplification. Ten to 20 full-length env
clones were isolated from plasma samples obtained at study entry
and at virologic failure. These full-length clones were used to assess
sequence heterogeneity and to guide appropriate design and
placement of forward and reverse primers. Despite the limitations
on amplicon size imposed by 454 sequencing, areas of no or
limited sequence heterogeneity that were suitable for primer
design could be identified in the regions immediately proximal and
distal to the V3-coding sequence. Primer degeneracy was
introduced when polymorphic positions in the target sequence
could not be avoided. The resulting primer sets amplified the
entire V3 loop-coding region of env with approximately 50–75
additional nucleotides of flanking sequence. (Specific primers used
were as follows: subject 07 1
st round 59-RCCAGTGGTRT-
CAACTCAAC-39 (07.1f) and 59-CCTRMGGRTGGTTGAAA-
AC-39 (07.1r), 2
nd round 59-GGTAGCCTAGCRGAAGGRAA-
G-39 (07.2f) and 59-CATTCCATTGCYTTKCACTA-39 (07.2r);
subject 18 1
st round 59-GCCAGTAGTATCAACTCAAC-39
(18.1f) and 59-CAATTTCTGGGTCCCCTCCTG-39 (18.1r),
2
nd round 59-GAAGGAACCTGTAAATATTAC-39 (18.2f) and
59-TCCAKTCTGYTKYACTAATG-39 (18.2r); subject 19 1
st
round 59-GGCAGTCTAGCAGARGAAGAGG-39 (19.1f) and
59-CCTGAGGATTGMTTAAAGGC-39 (19.1r), 2
nd round 59-
CARCTGAATGAATCTGTAAC-39 (19.2f) and 59-CCAGCTT-
KTTYCACTAATGTTAC-39 (19.2r); subject 47 1
st round 59-
GGCAGTYTAGCAGAAGATGAGG-39 (47.1f) and 59-GGT-
CCCCYCCTGAGGATTGG-39 (47.1r), 2
nd round 59-GATCT-
GAGAATTTCACAAACAATGC-39 (47.2f) and 59-TCCATG-
TTGCTCTACTAATG-39 (47.2r).
Conventional RT-PCR and PCR
The extracted RNA (60 mL) was added to the RT-PCR reaction
mix (final volume, 200 mL) that contained: 16RT buffer, forward
and reverse primers (200 nM each), dNTPs (200 mM), MgSO4
(1.7 mM), and SuperScript III RT/Platinum Taq enzyme mix
(Invitrogen, Carlsbad, CA). The reaction was transferred to thin-
walled PCR tubes (USA Scientific, Ocala, FL) in 50 mL aliquots
and subjected to the following conditions: 55uC for 30 minutes,
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for 30 seconds, and 68uC for 20 seconds (where T equals 5uC
below the lowest primer Tm). A final extension was performed at
68uC for 5 minutes, after which the aliquots were pooled into a
1.7 mL centrifuge tube, purified (MinElute PCR Purification Kit,
Qiagen), eluted into 30 mL of RNAse/DNAse-free water, and
used as template for a second round of amplification. The entire
30 mL of first round PCR product was added to a PCR reaction
(final volume 200 mL) that contained: 16 high fidelity buffer,
forward and reverse primers (200 nm each), dNTPs (200 mM),
MgSO4 (2 mM), and 4 units Platinum Taq High Fidelity enzyme
(Invitrogen, Carlsbad, CA). This reaction mixture was then
apportioned into 50 mL aliquots for thermocycling under the
following conditions: 94uC for 2 minutes, then 30 cycles of 94uC
for 30 seconds, (T)uC for 30 seconds and 68uC for 20 seconds
(where T equals 5uC below the lowest primer Tm) . After
amplification, the PCR products were purified as above prior to
454 sequencing.
Template Number Validation
The number of viral templates that were amplified by our
protocol was determined experimentally for a subset of plasma
samples. Using subject-specific primer sets, we used a real-time
RT-PCR assay with SYBR green detection to quantify RNA
templates from Subject 18 baseline and Subject 47 baseline and
week 16 plasma samples. Based on results of the HIV-1 Monitor
assays, a plasma volume corresponding to 56,828 RNA copies
from subject 18 baseline plasma, 196,425 copies from baseline
subject 47 plasma, and 47,108 copies of subject 47 week 16 plasma
were centrifuged at 17,0006g for 1 hour at 4uC. The pellet was
resuspended in 140 mL of plasma and extracted into 40 mLo f
buffer AVE using the QIAamp Viral RNA Mini Kit according to
manufacturer’s instructions (Qiagen). Ten microliters of this RNA
was used in a real-time PCR reaction that contained 16 Power
SYBR Green RT-PCR Mix, 16 RT Enzyme Mix, 200 nM of
forward and reverse primer, either 18.2 f/r or 47.2 f/r, in RNAse-
free water to a total volume of 50 mL (Power SYBR Green RNA-
to-Ct 1-Step Kit, Applied Biosystems). All samples were run in
duplicate. Each assay run contained two negative controls (a no
template control and a no reverse transcriptase control) and a
standard dilution curve. The standard curve with a dilution range
of 10
2–10
7 copies/mL was generated using RNA synthesized from
a plasmid that contained the dominant subject-specific V3 loop
sequence from the baseline (week 0) sample (TOPO-TA Kit,
[Invitrogen] and Megascript T7 High Yield Transcription Kit
[Ambion]). RNA was quantified spectrophotometrically, diluted,
aliquoted, and stored at 280uC; aliquots of RNA standards were
thawed only once before use. Real-time PCRs were performed
using an ABI Prism 7000 Sequence Detection System (Applied
Biosystems) for one cycle of 42uC for 40 minutes, one cycle of
95uC for 10 minutes and 45 cycles of 95uC for 15 sec and 55uC
for 1 minute. The standard curves generated for subjects 18 and
47 had an r
2 value of 0.974 and 0.995, respectively. The number
of amplified viral templates from subject plasma samples was
estimated by comparing the sample cycle threshold to the
threshold values for the known RNA copy numbers of the
standard curve (Supplementary Methods S1, Section 1.3).
Deep Sequencing, Data Filtering and Alignment
The V3 loop amplicons were first end-repaired with T4 DNA
polymerase and 59-phosphorylated with T4 Polynucleotide Kinase
(454/Roche). Amplicons were then column purified (MinElute,
Qiagen). Standard 454 adapters (one of which was biotinylated)
were then ligated to the amplicons using DNA ligase (454/Roche).
The modified amplicons including adapters were column purified
(MinElute, Qiagen), immobilized onto 28 mm streptavidin beads,
and blunt ended (454 adapters have a 59 overhang) using a Fill-in
polymerase (454/Roche). The single-stranded 454 library was
then isolated as described and quantified using an Agilent 2100
Bioanalyzer [3]. The 454 libraries were amplified on beads with
emulsion PCR and pyrosequenced as described [3]. All ultradeep
sequencing was performed using 454 GS FLX sequencing
platforms (Roche, Palo Alto, CA) at the Broad Institute at
Harvard and MIT. The raw data were processed, filtered, and
reported as readable sequence. Quality scores were derived using
predictors that improved on the default system software [31]. For
subject plasma samples, deep sequencing coverage (i.e., the
number of unique sequences generated) approximated the
maximum input viral RNA copy number. The depth of sequence
reads therefore varied from sample to sample.
V3 Loop Sequence Alignment Strategy
Because of the jagged start and stop positions and multiple
frameshifts and duplications, the standard multiple alignment tools
we used failed to give useful alignments of the 454 ultra deep
sequence nucleotide data. We therefore developed a series of
computational tools that align deep sequencing datasets for
subsequent analysis and interpretation. We first created an
alignment by hand from one sample to determine the type of
problem sequences we would encounter during the alignment
process. Sequences were generated in both the forward direction
and as reverse complements. Some were fragments that did not
span the entire V3 loop. Many were frame-shifted, with one- or
two-base insertions or deletions; there were frameshifting muta-
tions between almost every codon somewhere in the full alignment
in these very large data sets. Finally, some sequences contained
imperfect direct repeats, where the entire 454 sequence or a large
fraction of it was repeated. We did not know if a particular error
was due to HIV reverse transcriptase (RT) or was introduced
during the experimental procedure, but all the errors described
above would result in a non-viable virus, and so we excluded them
using an algorithm to generate a working V3 amino acid
alignment. The regions near the end of the sequences tended to
by the most error prone, so sequences were trimmed to the 117
bases encompassing the V3 loop and proximal glycosylation sites
for subsequent analyses.
Our filtering and alignment process began by compressing all
identical sequences into sets such that a single representative
sequence was included, and named to indicate how many times it
was found in the sample. These sequences were rank-ordered from
most to least common and sequentially numbered to give every
sequence a unique name. This compression step was repeated
several times through the filtering process – to the initial raw DNA
sequences, to the aligned DNA sequences trimmed to the region of
interest, and to the final protein alignment. We then generated a
reverse complement sequence from the entire set, and by aligning
each sequence in a pair-wise alignment to HXB2, checked the
similarity so that we kept only the forward direction version of the
sequence. Essentially any HIV strain can serve this purpose;
HXB2 was used for convenience, as it is a standard reference
strain. The goal was to confirm the forward or reverse direction of
the read and screen out aberrant sequences. Sequences that were
,60–70% similar to HXB2 even in the forward direction were
also excluded (this threshold was tuned so that we didn’t lose good
sequences in the more distant subtype C samples of subject 07;
within-patient consensus sequences can be also used with a higher
similarity threshold). Spot-checking of the sequences excluded due
to low similarity indicated that they generally comprised sequences
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direct repeats. We then eliminated all sequences that were too
short to span our minimum region of interest - the V3 and the two
proximal glycosylation sites (39 amino acids=117 bases).
We nextcreated pair-wisealignments ofeach sequenceto HXB2,
made a full DNAalignmentby sequentially combiningthe pair-wise
alignments, codon aligned the multiple sequence alignment using
HXB2 coding information (using the strategy we developed for the
GeneCutter tool at the Los Alamos database [www.hiv.lanl.gov]).
At this step, we segregated any sequences containing a frame shift
(single or double base gaps or insertions) within the V3 loop.
Sequences that had nearby compensatory changes were retained in
the working alignment. Then we translated all sequences and
recompressed the file to rename it according to the number of
protein sequence identities. All sequences with a stop codon were
removed, as well as a small number of sequences that did not fully
span the V3 loop that were not successfully filtered out. The
resulting protein alignment was reviewed and finalized using the
multiple alignment sequence editor MASE.
Table S3 shows how many sequences we eliminated at each
step of the filtering process. Sequences from subject 18 had a
recurrent frame shift in the middle of the V3 loop in a string of 6
A’s, a known common error in the 454 sequencing process– it was
the most common form in the week 02 and week 16 samples from
this subject, and is why such drastic cuts were made in those two
sequence sets [23]. New algorithms to improve base calls from the
raw data, as well as new experimental procedures are both under
development that will better address this issue in future studies.
HIV RT also introduces frameshifts and stop codons on its own, so
it is unclear whether a given error was introduced naturally by
HIV in vivo or through the sequencing protocol. Both are no doubt
contributing to the observed outcome. We identified similar
problem sequences in our control experiments that were based on
mixtures of cloned DNA (described below).
What we were left with after filtering was an essentially intact set
of V3 amino sequences, compressed, so that each unique form was
represented once, and each sequence was named for the sample,
the number of times it was found in the sample, and then ordered
from most to least common. These sets were used for all
subsequent analyses.
Amplicon Resequencing Control Experiments
A series of control experiments that determined the accuracy,
precision, and reproducibility of quantitative deep sequencing are
described in Supplementary Methods S1, sections 2 and 3.
Coreceptor Usage Prediction
Coreceptor usage for subjects 18, 19 and 47 was predicted using
the position-specific scoring matrices (PSSM) [32]. For subject 07,
coreceptor usage was determined phenotypically by testing
recombinant chimeric viruses that incorporated subject-derived
envs on CCR5- and CXCR4-expressing cell lines [21].
Deep Sequence Data Sets
Raw sequence files from this study have been deposited in the
NCBI Short Read Archive (http://www.ncbi.nlm.nih.gov/Traces/
sra/sra.cgi?cmd=table&f=sample&m=data&s=sample), accession
numbers SRS000811-000829.
Supporting Information
Supplementary Methods S1
Found at: doi:10.1371/journal.pone.0005683.s001 (0.22 MB
DOC)
Figure S1 Maximum likelihood trees by PhyML of two control
experiments. The comparison of shifts in the entropy of the subject
samples were based on the full sequence set, and so we determined
the entropy in each of the control experiments that was
contributed by experimental error, not the input diversity. The
entropy contributed by the experimental error in the two control
experiments was calculated by combining the sequences that
matched an input sequence as one category. The two controls
were indistinguishable, and had significantly lower entropy than
even the most conserved of the subject’s samples: control
experiment 1, H=0.401 [95% CI, 0.377–0.413 (based on 100
bootstrap resamplings)]; control experiment 2: H=0.414 [95%
CI, 0.396–0.426].
Found at: doi:10.1371/journal.pone.0005683.s002 (0.46 MB TIF)
Figure S2 Neighbor joining trees of all unique sequences in
control experiments 1 and 2. The input sequences A, B and C are
labeled in color and their locations are shown with vertical bars in
the trees. A star denotes probable recombinants and # highlights
two very divergent sequences in experiment 2.
Found at: doi:10.1371/journal.pone.0005683.s003 (0.16 MB TIF)
Figure S3 Neighbor-joining (NJ) trees over time. NJ trees for (A)
subject 07, (B) subject 19, and (C) subject 47 include all unique V3
forms found in each subject and also indicate the frequency of the
3 most common nucleotide forms at each time point. The most
common sequence at the first time point was used as an out-group
for the trees. For sub19 detail see Fig S5.
Found at: doi:10.1371/journal.pone.0005683.s004 (0.73 MB TIF)
Figure S4 Maximum likelihood (ML) trees of the unique V3
forms. The ML trees include only sequences found more than
0.1% of the time for (A) subject 07, (B) subject 19, and (C) subject
47. Amino acid sequences at branch points are shown. Week 0,
yellow; intermediate time point, red; VF, blue.
Found at: doi:10.1371/journal.pone.0005683.s005 (0.43 MB TIF)
Figure S5 Neighbor joining tree detail, subject 19. Quantitative
dynamic changes in V3 forms are highlighted through 17 weeks of
VCV therapy. Rare forms can exhibit dramatic proportional
increases or persist as minor forms; these forms acquire variants
over time, suggesting active replication. Other rare forms can be
lost entirely from the population. The absolute numbers of V3
loop forms are shown. The total numbers of V3 forms sequenced
for each time point are shown in Table S1.
Found at: doi:10.1371/journal.pone.0005683.s006 (0.84 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0005683.s007 (0.03 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0005683.s008 (0.03 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0005683.s009 (0.05 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0005683.s010 (0.04 MB
DOC)
Table S5
Found at: doi:10.1371/journal.pone.0005683.s011 (0.06 MB
DOC)
Table S6
Found at: doi:10.1371/journal.pone.0005683.s012 (0.04 MB
DOC)
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